Skip to main content

Table 3 Risk for DPN at different serum CEA quartiles (ORs [95% CIs])

From: High-normal serum carcinoembryonic antigen levels and increased risk of diabetic peripheral neuropathy in type 2 diabetes

 

Q1

Q2

Q3

Q4

p value for trend

n

101

100

102

99

–

DPN, n (%)

13 (12.9)

19 (19.0)

30 (29.4)

40 (40.4)

–

Model 0

1–reference

1.59 (0.74 to 3.42)

2.82 (1.37 to 5.80)

4.59 (2.26 to 9.31)

< 0.001

Model 1

1–reference

1.32 (0.60 to 2.90)

2.22 (1.05 to 4.72)

3.60 (1.72 to 7.56)

< 0.001

Model 2

1–reference

1.42 (0.59 to 3.43)

1.57 (0.65 to 3.83)

3.18 (1.32 to 7.62)

0.010

Model 3

1–reference

1.16 (0.37 to 3.63)

1.56 (0.52 to 4.66)

3.44 (1.12 to 10.55)

0.023

Model 4

1–reference

1.47 (0.45 to 4.82)

1.72 (0.54 to 5.53)

4.58 (1.39 to 15.06)

0.012

  1. Model 0: unadjusted;
  2. Model 1: adjusted for age, sex, diabetic duration, BMI, SBP, DBP, hypertension, alcohol consumption, and statins uses
  3. Model 2: additionally adjusted for ALT, TBI, albumin, lipid profiles, UA and eGFR
  4. Model 3: additionally adjusted for HbA1c, fasting C-peptide and glucagon
  5. Model 4: additionally adjusted for antidiabetic treatments